Immunogen, Inc.

Abbvie Inc.

Regeneron Pharmaceuticals, Inc.

Zoetis Belgium S.a

Dana-farber-cancer Institute Inc.

Regeneran Pharmaceuticals, Inc.

Ravi Chari

Walter A Blattler

Jijie Gu

Xiaolin Tang

John M Lambert

Emma Fung

Susan E Lacy

Meha Chhaya

Franco Tzul

Mary Kleppe

Victor S Goldmacher

Charles W Hutchins

Viktor S Goldmakher

Supriya Gupta

Camellia Zamiri

Dominic J Ambrosi

Mary Leddy

Yingchun Li

Jonathan A Hickson

Eve H Barlow

Louie Naumovski

Susan E Lappe

Jeffrey A Barbon

Diane M Lang

Deanna L Haasch

Xianhua Cao

Lorenzo Benatuil

Rajeeva Singh

Brenda A Kellogg

Charles F Scott, Jr

Linda J Kostuba

Simon E Moroney

Robert Yongxin Zhao

Michael Louis Miller

Wayne Charles Widdison

Tariq Ghayur

Wei Li

Nathan Elliott Fishkin

Godfrey W Amphlett

Wei Zhang

Feng Dong

Anca Clabbers

Yong Wang

Yong Dai

Deborah H Meshulam

Renee Miller

Jacqueline G Bixby

Lucia Eaton

Matthew Rieser

David P Pleynet

Sarah J Heighton

Hongsheng Xie

Albert R Collinson

Albert R Collison

Diana Bowley

Robert Lutz

Rita Steeves

Walter Blaettler

Susan E Lacey

Yelena Kovtun

Lyophilization methods for preparing protein formulations for long-term storage at room temperature or improved stability at refrigeration storage are provided. Specifically, the present application provides lyophilization methods to obtain a target percentage of residual moisture of a lyophilized product, such as 3-5% residual moisture. The secondary drying of the lyophilization can be conducted under controlling rate of desorption under a temperature which is similar to the shelf temperature of the primary drying. Alternatively, the lyophilization can be conducted without a distinguished secondary drying step.

Target residual moisture content for lyophilized drug product

This invention describes a method of conjugating a cell binding agent such as an antibody with an effector group (e.g., a cytotoxic agent) or a reporter group (e.g., a radionuclide), whereby the reporter or effector group is first reacted with a bifunctional linker and the mixture is then used without purification for the conjugation reaction with the cell binding agent. The method described in this invention is advantageous for preparation of stably-linked conjugates of cell binding agents, such as antibodies with effector or reporter groups. This conjugation method provides in high yields conjugates of high purity and homogeneity that are without inter-chain cross-linking and inactivated linker residues.

Methods for preparing a purified maytansinoid conjugate in a solution

Methods for preparing antibody-drug conjugates

The present disclosure encompasses NGF binding proteins, specifically to antibodies that are chimeric, CDR grafted and canonized antibodies, and methods of making and uses thereof. The antibodies, or antibody portions, of the disclosure are useful for detecting NGF and for inhibiting NGF activity, e.g., in a mammal subject suffering from a disorder in which NGF activity is detrimental.

Caninized anti-NGF antibodies and their use

Anti-NGF antibodies and their use

Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant DLL4 and/or VEGF expression or activity.

Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof

Binding proteins that bind one or more of VEGF, PDGF and/or their receptors, including antibodies, CDR-grafted antibodies, humanized antibodies, binding fragments, fusion proteins, and bispecific or multispecific proteins thereof are disclosed. Also disclosed are methods of making and using the binding proteins.

Antibodies against platelet-derived growth factor (PDGF)

The disclosure provides binding proteins that specifically bind to IL-1&#x3b1; and IL-1&#x3b2;. These binding proteins can be organized into DVD-Igs. These proteins can be used to modulate the activity of IL-1&#x3b1; and/or IL-1&#x3b2; and can be used for the treatment immunological diseases such as rheumatoid arthritis, osteoarthritis, psoriasis, multiple sclerosis, and other autoimmune diseases. In addition, their uses in the amelioration and/or treatment of pain in an individual suffering from a disease or disorder associated with IL-1 accumulation.

IL-1 binding proteins

Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases characterized by aberrant DLL4 and/or VEGF expression or activity.

The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more maytansinoids is covalently linked to the cell-binding agent via a non-cleavable linker and the cell-binding agent binds to cells of the selected cell population.

Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates

Growing community of inventors

Norwich, CT, United States of America

Ravi Chari